Risk assessment of environmental agents for developmental toxicity: Current and emerging approaches

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 396, Issue 1-2, 1997, Pages 205-218

  Dellarco, Vicki L ^a   Kimmel, Carole A ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Congenital anomaly; Developmental toxicity; In utero carcinogenesis; Risk assessment; Zygote

Indexed keywords

3 METHYLCHOLANTHRENE; ALKYLATING AGENT; AZACITIDINE; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DIMETHYLBENZ[A]ANTHRACENE; MITOMYCIN C; MUTAGENIC AGENT; PHENOBARBITAL; PHENYTOIN; POLYCHLORINATED BIPHENYL; RETINOIC ACID; RETINOID; TERATOGENIC AGENT; THALIDOMIDE;

CARCINOGENESIS; CONGENITAL MALFORMATION; DEVELOPMENTAL DISORDER; EMBRYO DEVELOPMENT; GENE EXPRESSION; GENETIC PREDISPOSITION; HUMAN; MONKEY; MOUSE; NONHUMAN; ORGANOGENESIS; PRIORITY JOURNAL; RABBIT; RAT; REPRODUCTIVE TOXICITY; REVIEW; RISK ASSESSMENT; ZYGOTE;

EID: 0031565923     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(97)00185-1     Document Type: Article

References (78)

1. US Environmental Protection Agency Maximum contaminant level goals and national primary drinking water regulations for lead and copper. Fed. Reg. 56(9):1991;26460-26564.
2. US Environmental Protection Agency Proposed regulations. Fed. Reg. 59(170):1994;45871.
3. US Department of Housing and Urban Development, Guidelines for the Evaluation and Control of Lead-based Paint Hazards in Housing, HUD-1539-LBP, US Department of Housing and Urban Development, Washington, DC, 1995.
4. Centers for Disease Control, Strategic Plan for the Elimination of Lead Poisoning, US Department of Health and Human Services, Washington, DC, 1991.
5. US Environmental Protection Agency Pesticide products containing dinoseb; notices. Fed. Reg. 51:1986;36645-36661.
6. US Environmental Protection Agency, Toxic Release Inventory, EPA-745-R-95-010, US Environmental Protection Agency, Washington, DC, 1994.
7. US Environmental Protection Agency, Environmental Health Threats to Children, EPA-175F-96-001, Office of the Administrator, US Environmental Protection Agency, Washington, DC, 1996.
8. Safe Drinking Water Act Amendments of 1996, Public Law 104-182, August 6, 1996, 110 Stat. 1617.
9. Food Quality Protection Act of 1996, Public Law 104-170, 100 Stat. 1489.
10. Shepard T.H. Human teratogenicity. Adv. Pediatr. 6(33):1986;225-268.
11. Bishop J., Kimmel C.A. Molecular and cellular mechanisms of early mammalian development: an overview of NIEHS/EPA developmental toxicity workshops. Reprod. Toxicol. 11:1997;285-291.
12. Waitzman N.J., Roman P.S., Scheffler R.M., Harris J.A. Economic costs of birth defects and cerebral palsy, United States, 1992. Morbid. Mortal. Weekly Rep. 44:1995;694-699.
13. Nelson K., Holmes L.B. Malformations due to presumed spontaneous mutations in newborn infants. N. Engl. J. Med. 320:1989;19-23.
14. US Environmental Protection Agency Guidelines for developmental toxicity risk assessment; notice. Fed. Reg. 56(234):1991;63798-63826.
15. J.L. Schardein, Chemically induced birth defects, in: F.J. DiCarlo, F.W. Oehme (Eds.), Drug and Chemical Toxicology, vol. 2, Marcel Dekker, New York, 1985, 841 pp.
16. N.A. Brown, Normal development: mechanisms of early embryogenesis, in: C.A. Kimmel, J. Buelke-Sam (Eds.), Developmental Toxicology, Raven, New York, 1994, pp. 15-52.
17. Redline R.W., Neish A., Holmes L.B., Collins T. Biology of disease: homeobox genes and congenital malformations. Lab. Invest. 66(6):1992;659-670.
18. L.B. Holmes, Developmental toxicology: scope of the problem, in: C.A. Kimmel, J. Buelke-Sam (Eds.), Developmental Toxicology, Raven, New York, 1994, pp. 3-12.
19. C.A. Kimmel, G.L. Kimmel, Principles of developmental toxicity risk assessment, in: R.D. Hood (Ed.), Handbook of Developmental Toxicology, CRC Press, New York, 1996, pp. 667-693.
20. National Research Council, Risk assessment in the federal government: managing the process, Committee on the Institutional Means for Assessment of Risks to Public Health, Commission on Life Sciences, National Research Council, National Academy Press, Washington, DC, 1983.
21. National Research Council, Science and judgment in risk assessment, Committee on Risk Assessment of Hazardous Air Pollutants, Commission on Life Sciences, National Research Council, National Academy Press, Washington, DC, 1994.
22. US Environmental Protection Agency Reproductive toxicity risk assessment guidelines. Fed. Reg. 61(212):1996;56274-56322.
23. A.K. Palmer, Implementing the ICH guideline for reproductive toxicity, in: L.E. Chasseaud (Ed.), Current Issues in Drug Development, II, Huntingdon Life Science, Huntingdon, 1993, pp. 32-52.
24. E.Z. Francis, Testing of environmental agents for developmental and reproductive toxicity, in: C.A. Kimmel, J. Buelke-Sam (Eds.), Developmental Toxicology, Raven, New York, 1994, pp. 403-428.
25. US Environmental Protection Agency, Health effects testing guidelines: prenatal developmental study (OPPTS 870.3700), and reproduction and fertility effects (OPPTS 870.3800), Office of Prevention, Pesticides and Toxic Substances, US Environmental Protection Agency, Washington, DC, 1996.
26. Generoso W.M., Rutledge J.C., Cain K.T., Hughes L.A., Downing D.J. Mutagen-induced fetal anomalies and death following treatment of females within hours after mating. Mutation Res. 199:1988;118-175.
27. Polifka J.E., Rutledge J.C., Kimmel G.L., Dellarco V.L., Generoso W.M. Skeletal deviation in mice offspring following zygotic exposure to ethylene oxide. Teratology. 53:1996;1-9.
28. Giavini E., Broccia M.L., Prati M., Vismara C. Effect of methods of administration on the teratogenicity of dinoseb in the rat. Arch. Environ. Contam. Toxicol. 15:1986;377-384.
29. Khera K.S. Ethylenethiourea: teratogenicity study in rats and rabbits. Teratology. 7:1973;243-252.
30. Chernoff N., Kavlock R.J., Rogers E.H., Carver B.D., Murray S. Perinatal toxicity of maneb, ethylenethiourea, and ethylenebisisothiocyanate sulfide in rodents. J. Toxicol. Environ. Health. 5:1979;821-834.
31. Khera K.S., Iverson F. Toxicity of ethylenethiourea in pregnant cats. Teratology. 18:1978;311-314.
32. Daston G.P., Yonker J.E., Powers J.F., Heitmeyer S.A. Difference in teratogenic potency of ethylenethiourea in rats and mice: relative contribution of embryonic and maternal factors. Teratology. 40:1989;555-566.
33. P.L. Hackett, M.R. Sikov, T.J. Mast, M.G. Brown, R.L. Burchbom, M.L. Clark, J.R. Decker, J.J. Evanoff, R.L. Rommereim, S.E. Rowe, R.B. Westerberg, Inhalation developmental toxicology studies of 1,3-butadiene in the rat, Final Report No. NIH-401-ES-40131, Pacific Northwest Laboratory, Richland, WA, 1987.
34. Dahl A.R., Sun J.D., Birnbaum L.S., Bond J.A., Griffith W.C., Mauderly J.L. Toxicokinetics of inhaled 1,3-butadiene in monkeys: comparison to toxicokinetics in rats and mice. Toxicol. Appl. Pharmacol. 110:1991;9-19.
35. Kimmel C.A., Rees D.C., Francis E.Z. Proceedings of the Workshop on the qualitative and quantitative comparability of human and animal developmental neurotoxicity. Neurotoxicol. Teratol. 12(3):1990;173-292.
36. Kimmel C.A. Quantitative approaches for human risk assessment for noncancer effects. Neurotoxicology. 11:1990;189-198.
37. Faustman E.M., Allen B.C., Kavlock R.J., Kimmel C.A. Dose-response assessment for developmental toxicity. I. Characterization of data base and determination of NOAELs Fundam. Appl. Toxicol. 23:1994;478-486.
38. Allen B.C., Strong P.L., Rice C.J., Hubbard S.A., Daston G.P. Benchmark dose analysis of developmental toxicity in rats exposed to boric acid. Fundam. Appl. Toxicol. 32:1997;194-204.
39. Rutledge J.C. Developmental toxicity induced during early stages of mammalian embryogenesis. Mutation Res. 396:1997;113-127.
40. Rutledge J.C., Generoso W.M., Shourbaji A., Cain K.T., Gans M., Oliva J. Developmental anomalies derived from exposure of zygotes and first-cleavage embryos to mutagens. Mutation Res. 296:1992;167-178.
41. Dellarco V.L. Genetic anomalies in mammalian germ cells and their significance for human reproductive and developmental risk. Environ. Health Perspect. 101(suppl. 2):1993;5-11.
42. W.M. Generoso, J.C. Rutledge, J. Aronson, Developmental anomalies: Mutational consequence of mouse zygote exposure, in: J.J. Moses, L.B. Russell (Eds.), Biology of Mammalian Germ Cell Mutagenesis, Banbury Report 34, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1990, pp. 311-319.
43. Bossert N.L., Hitselberger M.H., Iannaccone P.M. Protein alterations associated with N-methyl-N-nitrosourea exposure of preimplantation mouse embryos transferred to surrogate mothers. Teratology. 42:1990;147-159.
44. Katoh M., Cacheiro N.L.A., Cornett C.V., Cain K.T., Rutledge J.C., Generoso W.M. Fetal anomalies produced subsequent to treatment of zygotes awith ethylene oxide or ethyl methanesulfonate are not likely due to the usual genetic causes. Mutation Res. 210:1989;337-344.
45. Russell L.B., Bangham J.W., Stelzner K.F., Hunsicker P.R. High frequency of mosaic mutants produced by N-ethyl-N-nitrosourea exposure of mouse zygotes. Proc. Natl. Acad. Sci. USA. 85:1988;9167-9170.
46. Russell L.B., Bangham J.W. The paternal genome in mouse zygotes is less sensitive to ENU mutagenesis than the maternal genome. Mutation Res. 248:1991;203-209.
47. Dellarco V.L., Shourbaji A., Kimmel G.L., Rutledge J.C., Generoso W.M. Fetal anomalies produced from exposure of zygotes or early cleavage embryos to 5-azacytidine. Teratology. 45(5):1992;504.
48. Rutledge J.C., Shourbaji A.G., Hughes L.A., Polifka J.E., Cruz Y.P., Bishop J.B., Generoso W.M. Limb and lower-body duplications induced by retinoic acid in mice. Proc. Natl. Acad. Sci. USA. 91:1994;5436-5440.
49. Ehling U.H. Dominant mutations affecting the skeleton on offspring of X-irradiated mice. Genetics. 54:1966;1381-1389.
50. P.B. Selby, Induced mutation in mice and genetic risk assessment in humans, in: K.C. Bora, G.R. Douglas, E.R. Nestmann (Eds.), Chemical Mutagenesis, Human Population Monitoring and Genetic Risk Assessment, Prog. Mutation Res. vol. 3, 1982, pp. 275-288.
51. Lyon M.F., Renshaw R. Induction of congenital malformations in mice by parental irradiation: transmission to later generations. Mutation Res. 198:1988;277-283.
52. Nomura T. X-ray and chemically induced germ-line mutation causing phenotypical anomalies in mice. Mutation Res. 198:1988;309-320.
53. Selby, P.B., Experimental induction of dominant mutations in mammals by ionizing radiation and chemicals. Issues and Reviews in Teratology, Plenum, New York, 1990, pp. 181-253.
54. T. Nagao, Characteristics of male-mediated teratogenesis, in: D.R. Mattison, A.F. Olshan (Eds.), Male-mediated Developmental Toxicity, Plenum, New York, 1994, pp. 297-304.
55. Douglas G.R. The inclusion of an assay for inherited congenital malformations in the assessment of mutagenicity. Mutagenesis. 5:1990;421-423.
56. Jenkinson P.C., Anderson D., Gangolli S.D. Increased incidence of abnormal foetuses in the offspring of cyclophosphamide-treated male mice. Mutation Res. 188:1987;57-62.
57. Hales B.F., Crosman K., Robaire B. Increased postimplantation loss and malformations among the F2 progeny of male rats chronically treated with cyclophosphamide. Teratology. 45:1992;671-678.
58. Hales B.F., Smith S., Robaire B. Cyclophosphamide in the seminal fluid of treated males: transmission to females by mating and effect on progeny outcome. Toxicol. Appl. Pharmacol. 84:1986;423-430.
59. Mohrenweiser H., Zingg B. Mosaicism: the embryo as a target for induction of mutations leading to cancer and genetic disease. Environ. Mol. Mutagen. 25(26):1995;21-29.
60. Tomatis L., Narod S., Yamasaki H. Transgeneration transmission of carcinogenic risk. Carcinogenesis. 13:1992;145-151.
61. Herbst A.L., Ulfelder H., Poskanzer D.C. Adenocarcinoma of the vagina: associated of maternal stilbestrol therapy with appearance in young women. N. Engl. J. Med. 284:1971;878.
62. H. Kato, Y. Yoshimoto, W.J. Schull, Risk of cancer among children exposed to atomic bomb radiation in utero, in: N.P. Napalkov, J.M. Rice, L. Tomatis, H. Yamasaki (Eds.), Perinatal and Multigeneration Carcinogenesis, IARC Scientific Publication No. 96, International Agency for Research on Cancer, Lyon, France, 1989, pp. 365-374.
63. J.M. Rice, S. Rehm, P.J. Donovan, A.O. Perantoni, Comparative transplacental carcinogenesis by directly acting and metabolism-dependent alkylating agents in rodents and nonhuman primates, in: N.P. Napalkov, J M. Rice, L. Tomatis, H. Yamasaki (Eds.), Perinatal and Multigeneration Carcinogenesis, International Agency for Research on Cancer, Lyon, France, 1989, pp. 17-34.
64. Oda H., Zhang S., Tsurutani N., Shimizu S., Nnakatsuru Y., Aizawa S., Ishikawa T. Loss of p53 is an early event in the induction of brain tumors in mice by transplacental carcinogen exposure. Cancer Res. 57:1997;646-650.
65. Gardner J.J., Snee M.P., Hall H.J., Powell C.A., Downes S., Terrell J.D. Results of case-control study of leukemia and lymphoma among young people near Sellafield nuclear plant in West Cumbria. Br. Med. J. 300:1990;423-429.
66. Olshan A.F. Lessons learned from epidemiologic studies of environmental exposure and genetic disease. Environ. Mol. Mutagen. 25(26):1995;74-80.
67. Ketterer B., Harris J.M., Talaska G., Meyer D.J., Pemble S.E., Taylor J.B., Lang N.P., Kadlubar F.F. The human glutathione s-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ. Health Perspect. 98:1992;87-94.
68. Kadlubar F.F., Butler M.A., Kaderlik K.R., Chou H.-C., Lang N.P. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ. Health Perspect. 98:1992;69-74.
69. Buehler B.A., Delimont D., van Waes M., Finnell R.H. Prenatal prediction of risk of the fetal hydantoin syndrome. N. Engl. J. Med. 322:1990;1567-1572.
70. Raymond G.V., Buehler B.A., Finnell R.H., Holmes L.B. Anticonvulsant teratogenesis: 3. Possible metabolic basis. Teratology. 51:1995;55-56. (letter).
71. Ardinger H.H., Buetow K.H., Bell G.I. Association of genetic variation of the transforming growth factor-alpha gene with cleft lip and palate. Am. J. Hum. Genet. 45:1989;348-353.
72. Khoury M.J., Gomez-Farias M., Mulinare J. Does maternal cigarette smoking during pregnancy cause cleft lip and palate in offspring? Am. J. Dis. Child. 143:1989;333-337.
73. Hwang S.J., Beaty T.H., Panny S. Association study of transforming growth factor alpha (TGFa) TaqI polymorphism and oral clefts: indication of gene-environmental interaction in a population-based sample of infants with birth defects. Am. J. Epidemiol. 141:1995;629-636.
74. G.M. Shaw, E.J. Lammer, Incorporating molecular genetic variation and environmental exposures into epidemiologic studies of congenital anomalies, Reprod. Toxicol. 11 (1997) 275-280.
75. Dixon M.J., Garner J., Ferguson M.W.J. Immunolocalization of epidermal growth factor (EGF), EGF receptor and transforming growth factor alpha (TGFa) during murine palatogenesis in vivo and in vitro. Anat. Embryol. 184:1991;83-91.
76. Goldsworthy T.L., Conolly R.B., Fransson-Steen R. Apoptosis and cancer risk assessment. Mutation Res. 365:1996;71-90.
77. Wubah J.A., Ibrahim M.M., Gao X., Nguyer D., Pisano M.M., Knudsen T.B. Teratogen-induced eye defects mediated by p53-dependent apoptosis. Curr. Biol. 6(1):1996;60-69.
78. Schumacher R., Mai A., Gutjahr P. Association of rib anomalies and malignancy in childhood. Eur. J. Pediatr. 151:1992;432-434.